Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 6/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.32 |
| ▸ | RCOR1 | Q9UKL0 | 5/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077472 | 0.95 | PDE9A (0.35) | PDE9AESR1ESR2MAPK14 | |
| SCHEMBL2075721 | 0.91 | EHMT2 (0.33) | KDM1AEHMT2MEN1KMT2ARCOR1 | |
| SCHEMBL2078229 | 0.89 | AURKA (0.39) | KDM1AEHMT2MEN1KMT2ARCOR1 | |
| SCHEMBL13007364 | 0.88 | PDE9A (0.35) | PDE9ATSHREHMT2MAPK14 | |
| SCHEMBL2078452 | 0.86 | PDE9A (0.35) | PDE9ATSHR | |
| SCHEMBL2078117 | 0.86 | NQO2 (0.34) | — | |
| SCHEMBL2077826 | 0.86 | PDE9A (0.39) | PDE9A | |
| SCHEMBL2078591 | 0.86 | MAPT (0.38) | KDM1AEHMT2RCOR1 | |
| SCHEMBL2075684 | 0.85 | PDE9A (0.39) | PDE9A | |
| SCHEMBL2302147 | 0.85 | PDE9A (0.39) | PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | claimed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | claimed |
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2351751-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | CEPHALON, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | DPYD, P2RX5, P2RX7 | PDE9A 2783/4885CYP1A2 450/4885TSHR 1212/4885 |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | PDE9A 1977/4885CYP1A2 285/4885TSHR 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.